Liver health may impact how Weight-Loss drug works
NCT ID NCT05564104
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests how the experimental drug cagrilintide, being developed for weight management, is processed by the body in people with different levels of liver function. It involves 32 participants, including those with liver impairment and healthy volunteers. The goal is to see if liver problems change how the drug is absorbed and eliminated, which could guide future dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cagrilintide
What this could lead to
If successful, this study could help ensure that cagrilintide is used safely and effectively in people with liver problems for weight management.
What could go wrong
This is an early-phase study with only 32 participants, focused on drug processing rather than weight loss. Results may not predict real-world effectiveness or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APEX Research
München, 81241, Germany
-
Pharmaceutical Research Associates CZ, s.r.o.
Prague, 17000, Czechia
-
Summit Clinical Research s.r.o.
Bratislava, 83101, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, 901 22, Slovakia